- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03768986
A Reinforcement Intervention for Increasing HIV Testing Among At-Risk Women
African American and Latina women, as well as women living in poverty, are an identified health disparities population for HIV. Risks for HIV are compounded in this population when additional risk factors are present, including other sexually transmitted infections, intimate partner violence, substance use disorders, and homelessness or housing insecurity. Knowledge of one's HIV serostatus is key to linkage to care, improving HIV outcomes, and decreasing the spread of HIV. However, roughly a third of African American women and over half of Latina women have never been tested (CDC, 2016a). Barriers to testing include socioeconomical inequality, racial discrimination, low health literacy, and inadequate access to quality healthcare, among others. Novel methods for increasing HIV testing in this important health disparities group are greatly needed.
This study aims to test a reinforcement-based intervention to increase HIV testing and repeat testing among African American, Latina, and women living in poverty who have risk factors for HIV. We are partnering with multiple community-based organizations, several of which are non-traditional providers of HIV services (e.g., domestic violence agency, homeless shelter), to address systemic and structural issues that serve as barriers to testing. A primary aim is to evaluate the effectiveness of training community-based providers to deliver a reinforcement-based intervention for promoting HIV testing. In addition, we will compare standard referral services for HIV testing plus HIV risk reduction education to the same plus reinforcement for HIV testing (and repeat testing) using a randomized controlled trial with 334 participants. Women in both groups will be encouraged to seek HIV testing; be provided with the resources to do so (list of testing sites, bus passes if needed); and will receive basic education about HIV prevention using a widely available web-based resource (https://wwwn.cdc.gov/hivrisk/). Women in the reinforcement group will also be provided with $25 for undergoing an HIV test, with a $15 bonus if they have the test in the next 7 days ($40 total). During the next 12 months, they can receive an additional $25 for undergoing up to 2 more tests separated by 12 weeks, with $15 bonuses for each test completed within 7 days (+/- 7 days) of the scheduled date at 6- and 12-months post-initial test. It is hypothesized that the reinforcement intervention will result in greater proportions of women receiving an HIV test (and repeat HIV tests) compared to standard services.
In the proposed study, approximately 50 clinicians from our partner sites will be trained on both the non-reinforcement and reinforcement approaches to increasing HIV testing. Primary clinician outcomes are clinician knowledge and attitudes about HIV, testing, and reinforcement interventions. These will be assessed pre- and post-training and at 6-month intervals thereafter. A secondary outcome is clinician satisfaction with the training. Once clinicians are trained to competence, 334 women at our partner agencies will be randomized. Participants will be assessed at baseline and at 3-, 9-, and 15-month follow-ups. The primary outcome is objective reports of HIV testing, verified by testing centers. Secondary outcomes are HIV risk behaviors, test results, self-efficacy, client attitudes towards testing, and HIV knowledge. In addition, this study will include a careful analysis of costs of the reinforcement intervention to allow for estimates of its cost-effectiveness in increasing HIV testing.
The overall goal of this study is to determine whether a reinforcement intervention delivered by community providers is superior to standard referral procedures plus HIV education in increasing rates of HIV testing among women at the highest risk of HIV infection. A wide range of community partners that serve some of the highest risk groups of women were chosen to ensure highly generalizable results. If efficacious, the intervention has the potential for widespread adoption and implementation.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ruth Fetter
- Phone Number: 860-679-4556
- Email: fetter@uchc.edu
Study Locations
-
-
Connecticut
-
Farmington, Connecticut, United States, 06030
- UConn Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria for Clinician Participants:
- >6 months experience as a case manager, medical/nursing clinician or mental health/substance use therapist
- currently work with women at high risk for contracting HIV
- able to attend a training and participate in the evaluative components
- willing to conduct both standard HIV referral for testing and orientation to an online training and the same with reinforcement, depending on client's random assignment.
Exclusion Criteria for Clinician Participants
- planning to end employment at the agency within the next 3 months
Inclusion Criteria for Client Participants:
- female
- identifies as African American/black or Latina/Hispanic OR is living in poverty based on the most recent year's federal poverty guidelines
- 18 and older
- one or more high risk factors for HIV: intravenous drug use; or sexually active with past year partners with HIV or of unknown HIV status and no or inconsistent use of condoms
- English or Spanish speaking
- passes a quiz related to understanding the informed consent form
- has an address at which they expect to be able to receive mail and/or a phone to retrieve messages for the next 15 months
Exclusion Criteria for Client Participants:
- received a fourth-generation HIV test in the past 6 months
- HIV positive.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Treatment Group A
Standard referral for HIV testing and online HIV risk reduction training
|
Participants receive standard referral for HIV testing in the community.
Participants are encouraged to use the CDC's website to learn more about their individual risks for HIV and how to reduce them.
|
Experimental: Treatment Group B
Standard referral for HIV testing and online HIV risk reduction training plus reinforcement
|
Participants receive standard referral for HIV testing in the community.
Participants are encouraged to use the CDC's website to learn more about their individual risks for HIV and how to reduce them.
Systematic reinforcement of desired behaviors Participants will receive a monetary incentive for getting tested for HIV
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HIV testing by clients
Time Frame: From date of intervention until date of documented HIV test, assessed up to 15 months
|
HIV testing completion (i.e.
having test completed) will be verified by the testing sites
|
From date of intervention until date of documented HIV test, assessed up to 15 months
|
Clinician knowledge
Time Frame: Baseline and immediately post-training
|
Change in clinician knowledge will be measured through self-reports
|
Baseline and immediately post-training
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinician satisfaction with training
Time Frame: Post-training, up to 1 month
|
Satisfaction with training will be measured by self-report
|
Post-training, up to 1 month
|
HIV risk behaviors
Time Frame: Baseline and 3-month follow-up
|
Change in self-report measure: Human Immunodeficiency Virus Risk Behavior Scale, total score 0 to 55, higher scores represent worse outcomes
|
Baseline and 3-month follow-up
|
HIV Test Results
Time Frame: 15-month follow-up
|
Client self-reports
|
15-month follow-up
|
Client HIV knowledge
Time Frame: Baseline and 3-month follow-up
|
Change in knowledge as self-reported on Human Immunodeficiency Virus Knowledge Questionnaire, total score 0 to 18, higher scores represent better outcomes
|
Baseline and 3-month follow-up
|
HIV Risk Reduction Module Completion
Time Frame: 3-month follow-up
|
Self-reported completion of online HIV risk reduction modules
|
3-month follow-up
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kristyn Zajac, Ph.D., UConn Health
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 19-018-1
- R01MD013550 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Contingency Management
-
University of VirginiaNot yet recruitingContingency Management | Stimulant Use
-
UConn HealthNational Institute on Drug Abuse (NIDA)CompletedContingency Management | Cocaine Use DisorderUnited States
-
UConn HealthNational Heart, Lung, and Blood Institute (NHLBI)CompletedWeight Loss | Contingency ManagementUnited States
-
University of OklahomaCompletedTobacco Cessation | Tobacco Use | Tobacco Smoking | Smoking Cessation Financial Incentives | Socioeconomic Status | Contingency ManagementUnited States
-
University of OklahomaEnrolling by invitationTobacco Cessation | Tobacco Use | Tobacco Smoking | Smoking Cessation Financial Incentives | Socioeconomic Status | Contingency Management | PregnancyUnited States
-
UConn HealthNational Institute on Drug Abuse (NIDA)CompletedContingency Management | Exercise | Substance AbuseUnited States
-
UConn HealthNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedContingency Management | Alcohol AbuseUnited States
-
UConn HealthNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedContingency Management | Alcohol Use DisorderUnited States
-
UConn HealthNational Institute on Alcohol Abuse and Alcoholism (NIAAA)RecruitingContingency Management | Alcohol Use DisorderUnited States
-
Federal University of São PauloWashington State UniversityCompletedContingency Management | Substance Use Disorders | Addiction, CocaineBrazil
Clinical Trials on Standard referral for HIV testing
-
University of California, Los AngelesMedical University of South Carolina; Charles University, Czech Republic; Human...CompletedHuman Immunodeficiency VirusSouth Africa
-
University of California, Los AngelesEmory University; BroadReach Healthcare; USAID, South Africa; South African Department...CompletedHIV Infections | HIV Seropositivity | ARTSouth Africa
-
University of MiamiNational Institute on Drug Abuse (NIDA); University of California, San FranciscoCompleted
-
University of Kansas Medical CenterEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
University of PennsylvaniaNorthwestern University; Family Heart FoundationEnrolling by invitationFamilial HypercholesterolemiaUnited States
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...Enrolling by invitationHIV Infections | Opioid Use | Drug Use | Opioid-use DisorderUnited States
-
Kaiser PermanenteUniversity of California, San DiegoCompleted
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)Completed
-
Susan M. KieneNational Institute of Mental Health (NIMH); Rhode Island Hospital; Makerere UniversityCompletedHIV | Sexual BehaviorUganda
-
University of ArkansasDuke University; National Institute on Deafness and Other Communication Disorders... and other collaboratorsRecruitingHearing LossUnited States